Cross-reactive anti-E antibodies in COVID-19-vaccinated individuals were predominantly IgM and IgA, whereas anti-S antibodies in vaccinated individuals and anti-E antibodies in dengue-recovered patients were dominated by IgG1. Here, CD79A is linked to dengue disease.